Skip to main content
. 2022 Mar 12;2022:2249834. doi: 10.1155/2022/2249834

Figure 4.

Figure 4

Clinical efficacy of IL-12 and IL-23 blockade (ustekinumab). Patient before starting therapy (a, b), after 8 weeks from the introduction of the IL-12/IL-23 blocker (c, d), and after 16 weeks after the introduction of the IL-12/IL-23 blocker (e, f). Pictures presented are part of the private collection of Vesna M. Milicic and Ana B. Ravic Nikolic.